Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials – The Lancet Infectious Diseases Invited Commentary: Booster doses for inactivated COVID-19 vaccines: if, when, and for whom – The Lancet Infectious Diseases  

The post Phase 2 RCT: Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule. appeared first on Links Medicus.